(Q54269757)
Statements
Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. (English)
James G Krueger
Howard Sofen
Stacy Smith
Robert T Matheson
Craig L Leonardi
Cesar Calderon
Carrie Brodmerkel
Katherine Li
Kim Campbell
Stanley J Marciniak
Yasmine Wasfi
Yuhua Wang
Philippe Szapary
1 April 2014
133
4
1032-1040